HARTFORD, Conn., Oct. 9, 2025 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), announced today that over 81 percent of its Medicare Advantage (MA) members are in 2026 Medicare Advantage Prescription Drug (MAPD) plans that are rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS). Additionally, over 63 percent of Aetna Medicare Advantage members are in a 4.5-star plan for 2026.
"This year's Star Ratings reflect Aetna's strong fundamentals and unwavering commitment to delivering exceptional care experiences and better health outcomes for our Medicare Advantage members," said Aetna president Steve Nelson. "I am proud of the way our teams show up every day to support our members, enabling Aetna to serve as their trusted, reliable health care partner."
Aetna continues to be an industry leader in providing high-quality Medicare solutions, consistently ranking among the top tier of large publicly traded companies in CMS Star Ratings.
Our Star Ratings success includes high-quality performance for many of our largest MA contracts:
Every year, Medicare evaluates plans based on a 5-star rating system. The Star Ratings are posted at Medicare.gov. Visit AetnaMedicare.com to learn more about the 2026 Aetna Medicare plans. Or call 1-844-588-0041 (TTY: 711), 7 days a week, 8 AM to 8 PM. The Medicare Annual Enrollment Period runs from October 15 through December 7, 2025. A licensed agent may answer your call.
NOTE: Information in this release is based on 2026 Star Ratings data published by CMS on October 9, 2025, and MA and MAPD enrollment as of September 2025.
About CVS Health
CVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of June 30, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including highly rated Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.
About Aetna
Aetna, a CVS Health business, serves more than 37 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, and medical management capabilities, Medicaid health care management services, workers' compensation administrative services and health information technology products and services. Aetna's customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. For more information, visit Aetna.com.
Aetna Medicare is a HMO, PPO plan with a Medicare contract. Our SNPs also have contracts with State Medicaid programs. Enrollment in our plans depends on contract renewal. See Evidence of Coverage for a complete description of plan benefits, exclusions, limitations and conditions of coverage. Plan features and availability may vary by service area.
To send a complaint to Aetna, call the Plan or the number on your member ID card. To send a complaint to Medicare, call 1-800-MEDICARE (TTY users should call 1-877-486-2048), 24 hours a day/7 days a week. If your complaint involves a broker or agent, be sure to include the name of the person when filing your grievance.
©2025 Aetna Inc.
Y0001_6161702_2026_M
Media contact
Phil Blando
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor contact
Larry McGrath
800-201-0938
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$81.37 |
Daily Change: | 0.70 0.87 |
Daily Volume: | 6,614,190 |
Market Cap: | US$103.340B |
October 15, 2025 July 10, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load